In the present study, we examined the role of DDX5 in K562 cells derived from BCR-ABL-positive CML patients through its genetic deficiency and usage of the DDX5 inhibitor FL118. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.